20040633392

29 OCT 2004

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 November 2003 (13.11.2003)

PCT

(10) International Publication Number
WO 03/092697 A1

(51) International Patent Classification[7]: A61K 31/513, A61M 15/08

(21) International Application Number: PCT/GB03/01811

(22) International Filing Date: 28 April 2003 (28.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

10/139,193	2 May 2002 (02.05.2002)	US
10/191,481	8 July 2002 (08.07.2002)	US
10/232,798	29 August 2002 (29.08.2002)	US
10/233,126	29 August 2002 (29.08.2002)	US
10/267,896	8 October 2002 (08.10.2002)	US

(71) Applicant: CRAGMONT PHARMACEUTICALS, LLC [US/US]; 480 Grizzly Peak Blvd, Berkeley, CA 94708 (US).

(71) Applicant (for MG only): PAGET, Hugh, Charles, Edward [GB/GB]; Mewburn Ellis, York House, 23 Kingsway, London, Greater London WC2B 6HP (GB).

(72) Inventor: WEI, Edward, T.; 480 Grizzly Peak Blvd, Berkeley, CA 94708 (US).

(74) Agents: PAGET, Hugh, C.E. et al.; Mewburn Ellis, York House, 23 Kingsway, London, Greater London WC2B 6HP (GB).


(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THERAPEUTIC 1,2,3,6-TETRAHYDROPYRIMIDINE-2-ONE COMPOSITIONS AND METHODS THEREWITH



(1)

(57) Abstract: A therapeutic composition is provided that comprises a 1-R1-phenyl, 4-R2-phenyl substituted 1,2.3,6-tetrahydropyrimidine-2-one cold receptor agonist in a therapeutically effective amount. The composition preferably further comprises one or more pharmaceutically active drugs such as an anti-inflammatory glucocorticosteroid, a sympathomimetic amine decongestant, an antihistamine, a local anesthetic, menthol or a menthol analog, an immunosuppressant, and mixtures thereof. The cold receptor agonist may be represented by the general formula (1)-[R1-phenyl]-4-[R2-phenyl]-1,2,3,6-tetrahydropyrimidine-2-one wherein: R1 is -hydroxy, -chloro, - fluoro, -alkyl, -acetoxy, -trifluoromethyl ; and R2 is -nitro, -chloro, -fluoro, -alkyl, -trifluoromethyl. Therapeutic compositions of the invention elicit long-lasting cooling or soothing, particularly when formulated for delivery to suppress the sensations of itch and pain, such as for delivery to inflamed skin, to the mucous membranes of the eyelids, of the anogenital areas and of the airways, and to the enteric mucosa.

WO 03/092697 A1

162162

ACTION